TheScreener
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Deconstructing Return on Equity into Operating Profitability, Asset Efficiency, Tax Retention, and Financial Leverage.
| Company | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|
| ★ Laurus Labs Ltd.Active | 117.32 | 19.65 | 0.01 |
| Sun Pharmaceutical Industries Ltd.(SUNPHARMA) | 41.52 | 5.51 | 0.046 |
| Torrent Pharmaceuticals Ltd.(TORNTPHARM) | 79.00 | 20.38 | 0.019 |
| Apollo Hospitals Enterprise Ltd.(APOLLOHOSP) | 65.49 | 13.41 | 0.013 |
| Zydus Lifesciences Ltd. |
DuPont Analysis breaks down Laurus Labs Ltd.'s Return on Equity (16.8%) into core operational and financial drivers: Tax Burden (75.0%), Interest Burden (94.0%), EBIT Margin (13.0%), Asset Turnover (0.65x), and Financial Leverage (1.98x).
With a Debt-to-Equity of 0.33x and a Financial Leverage multiplier of 1.98x, Laurus Labs Ltd.'s ROE is predominantly driven by core operating profitability and pricing power (high quality earnings).
Laurus Labs Ltd. generates a Return on Capital Employed (ROCE) of 19.0% versus an ROE of 16.8%, indicating efficient total capital utilization across both equity and debt capital.
For informational and educational purposes only. Not investment advice. Data may be delayed or incomplete. Consult a SEBI-registered investment adviser before making investment decisions.
| 23.78 |
| 4.42 |
| 0.012 |
| Cipla Ltd.(CIPLA) | 29.66 | 3.34 | 0.011 |